X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Earnings for X4 Pharmaceuticals, Inc. (XFOR)
Earnings in 2023 (TTM): $-101,089,000
According to X4 Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-101,089,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of X4 Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-101,089,000 | $-101,167,000 |
| 2022 | $-93,839,000 | $-93,867,000 |
| 2021 | $-88,679,000 | $-88,696,000 |
| 2020 | $-61,983,000 | $-62,131,000 |
| 2019 | $-52,807,000 | $-56,604,000 |
| 2018 | $-43,021,000 | $-43,021,000 |
| 2017 | $-33,877,000 | $-33,877,000 |
| 2016 | $-22,975,000 | $-22,975,000 |
| 2015 | $-13,218,000 | $-13,218,000 |